The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change
Abstract
Medicine and Public Issues4 August 2009Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational ChangeFREEBryan R. Luce, PhD, MBA, Judith M. Kramer, MD, MS, Steven N. Goodman, MD, MHS, PhD, Jason T. Connor, PhD, Sean Tunis, MD, MSc, Danielle Whicher, MHS, and J. Sanford Schwartz, MDBryan R. Luce, PhD, MBAFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida., Judith M. Kramer, MD, MSFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida., Steven N. Goodman, MD, MHS, PhDFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida., Jason T. Connor, PhDFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida., Sean Tunis, MD, MScFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida., Danielle Whicher, MHSFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida., and J. Sanford Schwartz, MDFrom United BioSource Corporation, Bethesda, and Johns Hopkins Schools of Medicine and Public Health and Center for Medical Technology Policy, Baltimore, Maryland; Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania, and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Duke Translational Medicine Institute, Duke University, Durham, North Carolina;and Berry Consultants and University of Central Florida College of Medicine, Orlando, Florida.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-3-200908040-00126 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Join the dialogue on health care reform. Comment on the perspectives published in Annals and offer ideas of your own. All thoughtful voices should be heard.While advances in medical science have led to continued improvements in medical care and health outcomes, evidence of the comparative effectiveness of alternative management options remains inadequate for informed medical care and health policy decision making. The result is frequently suboptimal and inefficient care as well as unsustainable costs. To enhance or at least maintain quality of care as health reform and cost containment occurs, better evidence of comparative clinical and cost-effectiveness is required (1). The Amer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving the reporting of pragmatic trials: An extension of the CONSORT statement
Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., Moher, D., & groups, F. T. C. A. P. T. I. H. (. (2008) · BMJ · doi:10.1136/bmj.a2390 · Cited by 1,813
Self-citationTunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., et al. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.011 · Cited by 1,389
Self-citationExplanatory and Pragmatic Attitudes in Therapeutical Trials
Schwartz, D., & Lellouch, J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.012 · Cited by 1,252
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Berry, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1927 · Cited by 726
Comparative Effectiveness Research: A Report From the Institute of Medicine
Sox, H. C., & Greenfield, S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-3-200908040-00125 · Cited by 525
Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J.-M., & Ford, G. A. (2003) · Stroke · doi:10.1161/01.str.0000092527.33910.89 · Cited by 430
Statistical analysis and the illusion of objectivity
(1988) · Infectious Diseases Newsletter · doi:10.1016/0278-2316(88)90057-6 · Cited by 408
Assessing the Impact of Protocol Design Changes on Clinical Trial Performance
Getz, K. A., Wenger, J., Campo, R. A., Seguine, E. S., & Kaitin, K. I. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31816b9027 · Cited by 147
Cited by
Ford, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405
Best care at lower cost: the path to continuously learning health care in America
(2014) · Choice Reviews Online · doi:10.5860/choice.51-3277 · Cited by 1,363
A New Taxonomy for Stakeholder Engagement in Patient-Centered Outcomes Research
Concannon, T. W., Meissner, P., Grunbaum, J. A., McElwee, N., Guise, J.-M., Santa, J., Conway, P. H., Daudelin, D., Morrato, E. H., & Leslie, L. K. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2037-1 · Cited by 531
Beyond the intention-to-treat in comparative effectiveness research
Hernán, M. A., & Hernández-Díaz, S. (2012) · Clinical Trials · doi:10.1177/1740774511420743 · Cited by 528
“Randomized clinical trials (RCTs) are widely viewed as a key tool for comparative effectiveness research [1], and the intention-to-treat (ITT) comparison has long been regarded as the preferred analytic approach for many RCTs [2].”
MethodComparative Effectiveness Research: A Report From the Institute of Medicine
Sox, H. C., & Greenfield, S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-3-200908040-00125 · Cited by 525
Metadata
- Authors
- Luce, B. R., Kramer, J. M., Goodman, S. N., Connor, J. T., Tunis, S., Whicher, D., & Schwartz, J. S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-08-04
- Volume
- 151
- Issue
- 3
- Pages
- 206-209
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2125855951
- Cited by
- 330
- References
- 16
- FWCI
- 39.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change. https://app.cochat.ai/papers/10.7326/0003-4819-151-3-200908040-00126
- The paper
- Luce, B. R., Kramer, J. M., Goodman, S. N., Connor, J. T., Tunis, S., Whicher, D., & Schwartz, J. S. (2009). Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-151-3-200908040-00126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.